Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use

被引：0

作者：

Gane, E. ^{[1
]}

Seto, W. K. ^{[2
]}

Janssen, H. ^{[3
]}

Caruntu, F. A. ^{[4
]}

Kim, H. J. ^{[5
]}

Abdurakhmanov, D. ^{[6
]}

Nishiguchi, S. ^{[7
]}

Andrzej, H. ^{[8
]}

Bae, H. ^{[9
]}

Mo, S. ^{[10
]}

Suri, V. ^{[10
]}

Gaggar, A. ^{[10
]}

Flaherty, J. F. ^{[10
]}

Kao, J-H ^{[11
]}

Brunetto, M. ^{[12
]}

Buti Ferret, M. ^{[13
]}

机构：

[1] Auckland Clin Studies, Auckland, New Zealand

[2] Queen Mary Hosp, Hong Kong, Peoples R China

[3] Toronto Gen Hosp, Toronto, ON, Canada

[4] Natl Inst Infect Dis Matei Bals, Infect Dis, Bucharest, Romania

[5] Chung Ang Hosp, Seoul, South Korea

[6] Sechenov First Moscow State Med Univ, Moscow, Russia

[7] Hyogo Coll Med Hosp, Nishinomiya, Hyogo, Japan

[8] SP ZOZ Wojewodzki Szpital Zakazny Warszawie, Warsaw, Poland

[9] Asian Pacific Liver Ctr, Los Angeles, CA USA

[10] Gilead Sci Inc, Foster City, CA USA

[11] Natl Taiwan Univ, Taipei, Taiwan

[12] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy

[13] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：42 / 43

页数：2

共 50 条

[21] A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, G. Mani
Oberle, Corinna
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L. Y.
SWISS MEDICAL WEEKLY, 2019, : 25S - 25S
[22] Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection
Kaneko, Shun
Kurosaki, Masayuki
Tamaki, Nobuharu
Itakura, Jun
Kirino, Sakura
Watakabe, Keiya
Osawa, Leona
Okada, Mao
Wan, Wang
Shimizu, Takao
Higuchi, Mayu
Takaura, Kenta
Yasui, Yutaka
Tsuchiya, Kaoru
Nakanishi, Hiroyuki
Takahashi, Yuka
Izumi, Namiki
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E469 - E469
[23] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay
Ning, Qin
Agarwal, Kosh
Janssen, Harry L. A.
Pan, Calvin O.
Chuang, Wan Long
Izumi, Namiki
Fung, Scott
Shalimar
Brunetto, Maurizia
Flaherty, John
Mo, Shuyuan
Cheng, Cong
Lin, Lanjia
Gaggar, Anuj
Subramanian, Mani
Marcellin, Patrick
Gane, Edward
Hou, Jinlin
Buti, Maria
GUT, 2020, 69 : A75 - A76
[24] A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
Lampertico, Pietro
Buti, Maria
Ramji, Alnoor
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Yoon, Seung Kew
Kao, Jia-Horng
Chen, Chi-Yi
Tam, Edward
Khalili, Mandana
Bae, Ho
Ma, Xiaoli
Tak, Won Young
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Tan, Susanna
Liu, Yang
Wu, George
Subramanian, Mani
Hann, Hie-Won
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry
JOURNAL OF HEPATOLOGY, 2020, 73 : S67 - S68
[25] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Lim, Young-Suk
Chan, Henry Lik Yuen
Seto, Wai-Kay
Ning, Qing
Agarwal, Kosh
Janssen, Harry L. A.
Pan, Calvin Q.
Chuang, Wan Long
Izumi, Namiki
Fung, Scott K.
Shalimar
Brunetto, Maurizia R.
Flaherty, John F.
Mo, Shuyuan
Cheng, Cong
Lin, Lanjia
Gaggar, Anuj
Subramanian, Mani
Marcellin, Patrick
Gane, Edward J.
Hou, Jinlin
Buti, Maria
HEPATOLOGY, 2019, 70 : 126A - 127A
[26] FACTORS PREDICTIVE OF IMPROVEMENT OF RENAL FUNCTION AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE FROM TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH CHRONIC HEPATITIS B
Hong, Hyeyeon
Choi, Won-Mook
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Choi, Jonggi
HEPATOLOGY, 2024, 80 : S242 - S243
[27] A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Results
Khalili, Mandana
Lampertico, Pietro
Bae, Ho S.
Ma, Xiaoli
Ramji, Alnoor
Fung, Scott
Ahn, Sang Hoon
Kao, Jia-Horng
Tam, Edward
Halton, Patricia
Yee, Leland
Flaherty, John
Gaggar, Anuj
Liu, Yang
Wu, George
Hann, Hie-Won
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
Chan, Henry
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S543 - S543
[28] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
Chan, Henry Lik Yuen
Lampertico, Pietro
Ahn, Sang Hoon
Fung, Scott K.
Bae, Ho S.
Ramji, Alnoor
Lee, June Sung
Shafran, Stephen David
Gordon, Stuart C.
Phan, Charles G.
Tan, Susanna
Flaherty, John F.
Gaggar, Anuj
Wu, George
Suri, Vithika
Lau, Daryl
Byun, Kwan Soo
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
HEPATOLOGY, 2019, 70 : 287A - 288A
[29] The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Squillace, Nicola
Ricci, Elena
Menzaghi, Barbara
De Socio, Giuseppe Vittorio
Passerini, Simone
Martinelli, Canio
Mameli, Maria Sabrina
Maggi, Paolo
Falasca, Katia
Cordier, Laura
Celesia, Benedetto Maurizio
Salomoni, Elena
Di Biagio, Antonio
Pellicano, Giovanni Francesco
Bonfanti, Paolo
DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5515 - 5520
[30] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
Chan, Henry Lik Yuen
Lampertico, Pietro
Ahn, Sang Hoon
Fung, Scott
Bae, Ho
Ramji, Alnoor
Lee, Jung Sung
Shafran, Stephen
Gordon, Stuart
Phan, Charles
Tan, Susanna
Flaherty, John
Gaggar, Anuj
Wu, George
Suri, Vithika
Lau, Daryl
Byun, Kwan Soo
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
GUT, 2020, 69 : A74 - A75

← 1 2 3 4 5 →